Pieris Achieves Preclinical Milestone Payment in Sanofi Collaboration

Freising, Germany, February 10, 2014 – Pieris AG has achieved a preclinical milestone within its R&D collaboration with Sanofi (EURONEXT: SAN and NYSE: SNY), triggering an undisclosed payment, the company announced today. The milestone relates to the generation of sub-nanomolar Anticalins^®against multiple targets within a single therapeutic program, forming the building blocks for a multispecific program.

“This achievement highlights the versatility and speed of the Anticalin platform, in particular since these drug candidates were characterized in approximately six months from project initiation,” Stephen Yoder, CEO of Pieris, stated. “Our R&D collaborations are entering into a new phase of maturity, demonstrated by the repeated achievement of development milestones.” Mr. Yoder will provide further update on Pieris’ partnered and proprietary pipeline in a presentation 11:30 am EST Tuesday, February 11, 2014, at the 16^th Annual BIO CEO and Investor Conference taking place at the Waldorf Astoria in New York City.

Anticalins are therapeutic proteins derived from human lipocalins, rationally engineered to solve for the pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms.

About Pieris

Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin^® technology to create differentiated drugs that are safer and more effective than conventional approaches. Exclusive to Pieris, Anticalins promise to address high-unmet medical needs and expand the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures. www.pieris-ag.com.

--END--

For more information, please contact:

Stephen Yoder, CEO
Pieris AG
media@pieris-ag.com
+49 (0) 8161 1411 400

Gretchen Schweitzer
gschweitzer@macbiocom.com
+49 172 861 8540

Additional information is available at www.pieris-ag.com.

Anticalin^®, Anticalins^® are registered trademarks of Pieris AG

Released February 10, 2014